Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
PD-L1 expression + HER-2 overexpression
i
Other names:
PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule, ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
2064
;
29126
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
HER-2 amplification (129)
PD-L1 amplification (6)
EGFR amplification + ERBB2 amplification (1)
EGFR exon 19 deletion + HER-2 amplification (1)
HER-2 amplification + MET amplification (1)
HER-2 amplification + PTEN deletion (1)
HER-2 exon 19 deletion (1)
MYC amplification + HER-2 amplification (1)
PD-L1 deletion (1)
HER-2 amplification + CDK12 amplification (0)
YES1 amplification + HER-2 amplification (0)
HER-2 amplification (129)
PD-L1 amplification (6)
EGFR amplification + ERBB2 amplification (1)
EGFR exon 19 deletion + HER-2 amplification (1)
HER-2 amplification + MET amplification (1)
HER-2 amplification + PTEN deletion (1)
HER-2 exon 19 deletion (1)
MYC amplification + HER-2 amplification (1)
PD-L1 deletion (1)
HER-2 amplification + CDK12 amplification (0)
YES1 amplification + HER-2 amplification (0)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
PD-L1 expression + HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
PD-L1 expression + HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
pembrolizumab + margetuximab-cmkb
Sensitive: C3 – Early Trials
pembrolizumab + margetuximab-cmkb
Sensitive
:
C3
pembrolizumab + margetuximab-cmkb
Sensitive: C3 – Early Trials
pembrolizumab + margetuximab-cmkb
Sensitive
:
C3
PD-L1 expression + HER-2 overexpression
Gastric Cancer
PD-L1 expression + HER-2 overexpression
Gastric Cancer
pembrolizumab + margetuximab-cmkb
Sensitive: C3 – Early Trials
pembrolizumab + margetuximab-cmkb
Sensitive
:
C3
pembrolizumab + margetuximab-cmkb
Sensitive: C3 – Early Trials
pembrolizumab + margetuximab-cmkb
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login